UPDATED: Kardashian Social Media Posts Lead to Trouble for Drug Company

UPDATED: Kardashian Social Media Posts Lead to Trouble for Drug Company
August 31, 2015

Kim Kardashian can't stay out of the headlines, even in consumer news.

The social media and television personality has been showing her support for morning sickness drug Diclegis over the past month through her Facebook, Instagram, and Twitter accounts, and the endorsements have caught the eye of the U.S. Food and Drug Administration (FDA).

According to Bloomberg News, The agency has sent a warning letter to drug maker Duchesnay requesting that the firm "immediately cease misbranding" the drug or stop selling it.

Kardashian, who claims that she is "partnering" with Duchesnay to raise awareness about morning sickness, includes only the benefits of using Diclegis in her posts while ignoring all risk information and drug limitations, a violation of FDA policy.

In a letter to Duchesnay, the FDA states: "By omitting the risks associated with DICLEGIS, the social media post misleadingly fails to provide material information about the consequences that may result from the use of the drug and suggests that it is safer than has been demonstrated."

The links cited by the FDA could not be found, indicating that Kardashian has taken down the posts.

In an e-mail, a Duchesnay spokesperson said the company "acknowledges that its communications, including in social media as in this particular instance, need to be in accordance with applicable rules and regulations." Duchesnay "will take quick action in responding to the FDA's letter and immediately and effectively address any issues."

UPDATE: Kardashian took to Instagram this weekend with a "#CorrectiveAd." She posted a picture of herself with a bottle of Diclegis along with another endorsement of the product, but this time included information on the safety risks associated with the drug, in accordance with FDA protocol.